Tvardi Therapeutics Stock (NASDAQ:TVRD)
Previous Close
$27.34
52W Range
$8.14 - $34.31
50D Avg
$26.33
200D Avg
$16.66
Market Cap
$279.24M
Avg Vol (3M)
$62.49K
Beta
0.25
Div Yield
-
TVRD Company Profile
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).